Cann Group Limited is supplying medicinal cannabis for Australian clinical trial assessing quality of life impacts for advanced cancer patients.
The trial, which is being led by Olivia Newton-John Cancer Research Institute (ONJCRI), saw Cann Group supply a locally cultivated and manufactured product from a strain that was initially developed by Agriculture Victoria.
The Phase I trial, which commenced in late September 2020, is investigating the safety and tolerability of the drug, with Phase II to evaluate the efficacy of the drug by assessing global Quality of Life in participating patients, as well as other domains including pain, anorexia, nausea, anxiety and sleep.
Cann Group CEO Peter Crock said the Company is pleased to be able to contribute to the ongoing clinical evaluation of medicinal cannabis as a potential therapy for cancer patients.
“There is a large and growing body of anecdotal evidence supporting the role of medicinal cannabis in pain control, reducing nausea and treating other side-effects and quality of life outcomes associated with cancer treatment,” he noted.
“It is important, however, that we continue to build a solid body of evidence via rigorously controlled clinical trials such as this.”
ONJCRI’s Director Prof Matthias Ernst added: “This is a first-of-its-kind clinical trial in Victoria and one of only a few being conducted world-wide. As a team, we are incredibly excited to be leading this trial. As with all of our other research efforts, we are focussed on finding new options for people impacted by cancer.”
